

Veredus Laboratories' VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 Receives Provisional Authorisation from the Health Sciences Authority (HSA) in Singapore for *In vitro* Diagnostic (IVD) Use

Singapore, June 04, 2020 – Veredus Laboratories Pte Ltd “Veredus” has obtained Provisional Authorisation from Singapore Health Sciences Authority (HSA) for VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 for use as an *In vitro* Diagnostic (IVD) test in Singapore. Veredus can supply to healthcare institutions, private hospitals, medical clinics and clinical laboratories licensed under the Private Hospitals and Medical Clinics (PHMC) Act in Singapore.

VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is a one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based IVD test intended for the qualitative detection of nucleic acid belonging to SARS-CoV-2. This test is suitable and easily adaptable for use in qPCR cycler with FAM and HEX (HIC) detection channels.

Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories said, “In response to this COVID-19 pandemic situation, our team worked rapidly to develop an updated with increased sensitivity and user friendliness real-time RT-PCR test to detect SARS-CoV-2. This updated assay provides enhanced tolerance against gene mutations by targeting dual viral N gene targets as well as an inclusion of the human RPP30 gene as the Human Internal Control within the assay. We are proud and excited to receive this Provisional Authorisation IVD from HSA and for Veredus to support laboratories in their diagnostic effort for COVID-19.”

For more information please contact:

Dr Damian Foo, Assistant Product Director
Veredus Laboratories Pte Ltd
Email: damian.foo@vereduslabs.com
Mobile: +65 9649 0569

About Veredus Laboratories Pte Ltd

Veredus was founded in 2003 and launched its first products in 2005. Veredus manufactures and markets the VerePLEX™ Biosystem to provide innovative multiplexed molecular solutions in the food safety, biosurveillance, infectious disease and custom testing markets. The VerePLEX™ Biosystem works in conjunction with VereChip™ - a Lab-on-

83 Science Park Drive #04-02
Singapore 118258
T: (65) 6496 8600 F: (65) 6779 2680

vereduslabs.com

Company Registration Number: 200305085G

Chip platform that combines Micro-Electro-Mechanical Systems (MEMS) with micro-fluidics to integrate multiplexed nucleic acid amplification with microarray detection for rapid, cost-effective, and accurate analysis of biological materials. Veredus Laboratories is now a wholly-owned subsidiary of Sekisui Chemical Co. Ltd.

In a combined effort against COVID-19, VerePLEX™ Biosystem and VereCoV™ (Lab-on-Chip) Detection Kit were previously issued with similar Provisional Authorisation from Singapore HSA on 18 Feb for use as an IVD product in Singapore.